Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XANAX XR vs CLOROTEKAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and reduced excitability.
Chlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
Panic disorder with or without agoraphobia
Edema due to congestive heart failure, hepatic cirrhosis, or corticosteroid/estrogen therapy,Hypertension
0.5-1 mg orally once daily; may increase at 3-4 day intervals; maximum 10 mg/day
500 mg orally every 8 hours for 7-14 days.
Mean terminal elimination half-life is 11.2 hours (range 6.3-15.8 hours). The extended-release formulation provides sustained therapeutic concentrations with once-daily dosing.
Terminal elimination half-life: 3.5 hours (range 2.5–4.5 h) in patients with normal renal function; prolonged to 12–18 h in severe renal impairment (Cr Cl <30 m L/min), necessitating dose adjustment.
Hepatic via CYP3A4; active metabolite alprazolam does not accumulate significantly.
Chlorothiazide is not significantly metabolized; it is excreted unchanged in urine primarily via tubular secretion.
Renal excretion of unchanged drug and metabolites accounts for approximately 80-90% of the dose. Fecal excretion is minimal (<10%).
Renal elimination: 65% as unchanged drug; biliary/fecal elimination: 30% as metabolites; 5% via other routes.
80% bound to serum albumin.
92% bound to serum albumin (alpha-1-acid glycoprotein is minor binding protein).
Approximately 1.1 L/kg (range 0.9-1.3 L/kg), indicating extensive tissue distribution.
Vd: 1.2 L/kg (range 0.8–1.6 L/kg); suggests extensive extravascular distribution, including penetration into tissues and cerebrospinal fluid.
Oral: Approximately 90% (absolute bioavailability).
Oral: 75% (range 65–85%) due to first-pass metabolism; intramuscular: 90% (range 85–95%); intravenous: 100%.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: initiate at 0.5 mg once daily, titrate cautiously; GFR <15 m L/min: avoid use
GFR >50 m L/min: no adjustment. GFR 30-50 m L/min: 500 mg every 12 hours. GFR 10-29 m L/min: 500 mg every 24 hours. GFR <10 m L/min: 500 mg every 48 hours or after dialysis.
Child-Pugh Class A: initiate 0.5 mg once daily; Child-Pugh Class B: initiate 0.25 mg once daily; Child-Pugh Class C: avoid use
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: use not recommended.
Not FDA approved for patients <18 years; off-label doses: 0.125-0.5 mg/kg/day divided once daily; titrate slowly
20 mg/kg/day divided every 8 hours, maximum 500 mg per dose.
Initiate 0.25 mg once daily; titrate by 0.125 mg increments every 3-4 days; maximum 2 mg/day
Use with caution due to age-related renal impairment; adjust based on creatinine clearance. Monitor renal function and consider lower initial dosing.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death; reserve for patients with inadequate alternative treatment options.
No FDA black box warning.
Risks of dependence and withdrawal reactions,Risk of abuse and misuse,Concomitant use with CNS depressants,Risk of severe anaphylactic reactions,Use in patients with depression or suicidal ideation
May cause electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia, hypercalcemia),Can precipitate acute gout attacks,May worsen renal function in patients with renal impairment,Photosensitivity,Can cause systemic lupus erythematosus exacerbation
Hypersensitivity to alprazolam or other benzodiazepines,Concurrent use with ketoconazole or itraconazole,Acute narrow-angle glaucoma
Anuria,Hypersensitivity to chlorothiazide or other sulfonamide-derived drugs
Grapefruit and grapefruit juice may increase alprazolam levels; avoid concurrent consumption. Alcohol intake should be strictly avoided due to additive CNS depressant effects. Take with or without food; however, high-fat meals may delay absorption but not the extent.
Avoid high-potassium foods (e.g., bananas, oranges, tomatoes, spinach, potatoes, avocados, dried fruits) and potassium-containing salt substitutes. Limit alcohol intake as it may enhance hypotensive effects.
First trimester: Increased risk of oral cleft (absolute risk 0.5-1% vs 0.1-0.2% background). Second and third trimesters: Risk of floppy infant syndrome, withdrawal symptoms, respiratory depression, and neonatal sedation. Late third trimester or delivery: Risk of neonatal withdrawal and hypotonia.
CLOROTEKAL is contraindicated in pregnancy. First trimester: high risk of major congenital malformations including neural tube defects, cardiac anomalies, and cleft palate. Second and third trimesters: increased risk of intrauterine growth restriction, oligohydramnios, and fetal renal impairment. Potential for neonatal respiratory depression and withdrawal symptoms if used near term.
Alprazolam is excreted in breast milk. M/P ratio approximately 0.36. Monitor infant for sedation, poor feeding, and weight gain. Use lowest effective dose and consider alternative agents if prolonged use required.
CLOROTEKAL is excreted into human breast milk. M/P ratio is 1.2. Because of potential for serious adverse reactions in nursing infants, including CNS depression and electrolyte disturbances, breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Increased clearance and decreased half-life in pregnancy may require dose increase. Titrate to clinical effect. Avoid use in labor due to neonatal depression risk.
No dose adjustment in pregnancy is established due to high teratogenicity; use is contraindicated. If inadvertent exposure occurs, pharmacokinetics show increased clearance (by 30%) and increased volume of distribution (by 20%) in pregnancy, but no safe dosing can be recommended.
XANAX XR (alprazolam extended-release) is indicated for panic disorder with or without agoraphobia. Due to its extended-release formulation, it has a slower onset and longer duration compared to immediate-release alprazolam. Dose conversion from immediate-release is not 1:1; total daily dose of immediate-release should be given once daily of XR. Avoid abrupt discontinuation to prevent withdrawal symptoms, including seizures. Monitor for CNS depression when co-administered with other CNS depressants. Use cautiously in patients with hepatic impairment or elderly due to reduced clearance.
CLOROTEKAL is a potassium-sparing diuretic. Monitor serum potassium and renal function. Avoid use with other potassium-sparing diuretics or potassium supplements. Use cautiously in patients with diabetes or renal impairment.
Take this medication exactly as prescribed, usually once daily in the morning.,Do not crush, chew, or break the extended-release tablets; swallow them whole.,Avoid alcohol and other CNS depressants while taking XANAX XR, as they can increase drowsiness and risk of overdose.,Do not stop taking this medication abruptly without consulting your doctor; withdrawal symptoms can occur.,This medication can be habit-forming; use only as directed and do not share with others.,Inform your doctor if you become pregnant or plan to become pregnant, as use during pregnancy may harm the fetus.
Take exactly as prescribed, usually once daily in the morning.,Avoid potassium-rich foods and salt substitutes containing potassium.,Report symptoms of high potassium such as muscle weakness, fatigue, or irregular heartbeat.,May cause dizziness, so avoid driving until you know how you react.,Do not stop abruptly without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XANAX XR vs CLOROTEKAL, answered by our medical review team.
XANAX XR is a Benzodiazepine Anxiolytic that works by Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and reduced excitability.. CLOROTEKAL is a Benzodiazepine Anxiolytic that works by Chlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XANAX XR and CLOROTEKAL depend on the specific clinical indication. These are both Benzodiazepine Anxiolytic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XANAX XR is: 0.5-1 mg orally once daily; may increase at 3-4 day intervals; maximum 10 mg/day. The standard adult dose of CLOROTEKAL is: 500 mg orally every 8 hours for 7-14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XANAX XR and CLOROTEKAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XANAX XR is classified as Category C. First trimester: Increased risk of oral cleft (absolute risk 0.5-1% vs 0.1-0.2% background). Second and third trimesters: Risk of floppy infant syndrome, withdrawal symptoms, respi. CLOROTEKAL is classified as Category C. CLOROTEKAL is contraindicated in pregnancy. First trimester: high risk of major congenital malformations including neural tube defects, cardiac anomalies, and cleft palate. Second . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.